GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Net Issuance of Debt

ORKA (Oruka Therapeutics) Net Issuance of Debt : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Oruka Therapeutics's net issuance of debt for the three months ended in Mar. 2025 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Oruka Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Oruka Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Net Issuance of Debt Chart

Oruka Therapeutics Annual Data
Trend Dec24
Net Issuance of Debt
-

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25
Net Issuance of Debt 24.98 - - - -

Oruka Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Net Issuance of Debt
Comparable Companies
MGTX AUTL SEPN DNA SAGE ATAI MBX PGEN TECX CYDY VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
HQ1:Germany
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.